Open Access. Powered by Scholars. Published by Universities.®
- Discipline
-
- Health Law and Policy (11)
- Food and Drug Law (7)
- Administrative Law (4)
- Intellectual Property Law (3)
- Agriculture Law (2)
-
- Chemicals and Drugs (2)
- Consumer Protection Law (2)
- Environmental Law (2)
- Land Use Law (2)
- Life Sciences (2)
- Medical Jurisprudence (2)
- Medicine and Health Sciences (2)
- Social and Behavioral Sciences (2)
- Torts (2)
- Advertising and Promotion Management (1)
- Agricultural Science (1)
- Agricultural and Resource Economics (1)
- Agriculture (1)
- Agronomy and Crop Sciences (1)
- Amino Acids, Peptides, and Proteins (1)
- Biological Engineering (1)
- Biomedical Devices and Instrumentation (1)
- Biomedical Engineering and Bioengineering (1)
- Biotechnology (1)
- Business (1)
- Civil Law (1)
- Engineering (1)
- Food Biotechnology (1)
- Food Science (1)
- Institution
-
- Selected Works (6)
- SelectedWorks (4)
- Case Western Reserve University School of Law (2)
- Brigham Young University Law School (1)
- Georgetown University Law Center (1)
-
- Maurer School of Law: Indiana University (1)
- Pepperdine University (1)
- Saint Louis University School of Law (1)
- Touro University Jacob D. Fuchsberg Law Center (1)
- University of Kentucky (1)
- University of Maryland Francis King Carey School of Law (1)
- University of New Hampshire (1)
- University of Richmond (1)
- University of San Diego (1)
- Publication
-
- Faculty Publications (2)
- Keren F. Bisnauth (2)
- Vincent J Roth Esq (2)
- Faculty Scholarship (1)
- Fazal Khan (1)
-
- Georgetown Law Faculty Publications and Other Works (1)
- IP Theory (1)
- Jessie Nibley (1)
- Journal of Health Care Law and Policy (1)
- Kentucky Law Journal (1)
- Law Faculty Scholarship (1)
- Parker Tresemer (1)
- Patricia E. Salkin (1)
- Pepperdine Law Review (1)
- Richard A. Daynard (1)
- Richmond Journal of Law & Technology (1)
- Saint Louis University Law Journal (1)
- San Diego Law Review (1)
- Scholarly Works (1)
- Vincent Y. Ling (1)
- Publication Type
- File Type
Articles 1 - 23 of 23
Full-Text Articles in Law
The Fda Sends Smoke Signals To Big Tobacco: Will The Fda Suffer Backlash, Will Alcohol Be Regulated Next, And Will The Health Of Americans Prevail?, Angela Turriciano
The Fda Sends Smoke Signals To Big Tobacco: Will The Fda Suffer Backlash, Will Alcohol Be Regulated Next, And Will The Health Of Americans Prevail?, Angela Turriciano
Pepperdine Law Review
No abstract provided.
Reducing Unlawful Prescription Drug Promotion: Is The Public Health Being Served By An Enforcement Approach That Focuses On Punishment?, Vicki W. Girard
Reducing Unlawful Prescription Drug Promotion: Is The Public Health Being Served By An Enforcement Approach That Focuses On Punishment?, Vicki W. Girard
Georgetown Law Faculty Publications and Other Works
Despite the imposition of increasingly substantial fines and recently successful efforts to impose individual liability on corporate executives under the Park doctrine, punishing pharmaceutical companies and their executives for unlawful promotional activities has not been as successful in achieving compliance with the Federal Food, Drug, and Cosmetic Act (FD&C Act) as the protection of the public health demands. Over the past decade, the Food and Drug Administration (FDA) and the Department of Justice (DOJ) have shifted their focus from correction and compliance to a more punitive model when it comes to allegedly unlawful promotion of pharmaceuticals. The shift initially focused …
Will Fda Data Exclusivity Make Biologic Patents Passé?, Vincent J. Roth Esq
Will Fda Data Exclusivity Make Biologic Patents Passé?, Vincent J. Roth Esq
Vincent J Roth Esq
Much controversy has ensued over the current 12 year data exclusivity period afforded biosimilars pursuant to the Biologics Price Competition and Innovation Act of 2009 (the “BPCI”) that was recently enacted in March 2010, as part of President Obama’s Patient Protection and Affordable Care Act (the “PPACA”), to create a biosimilar market in the US. In fact, the BPCI, itself, has been controversial and just barely survived judicial scrutiny when the US Supreme Court upheld the PPACA on June 28, 2012 in a 5-4 vote. Many commentators speculate whether data exclusivity will overtake patents as the preferred method of intellectual …
Will Fda Data Exclusivity Make Biologic Patents Passé?, Vincent J. Roth Esq
Will Fda Data Exclusivity Make Biologic Patents Passé?, Vincent J. Roth Esq
Vincent J Roth Esq
Much controversy has ensued over the current 12 year data exclusivity period afforded biosimilars pursuant to the Biologics Price Competition and Innovation Act of 2009 (the “BPCI”) that was recently enacted in March 2010, as part of President Obama’s Patient Protection and Affordable Care Act (the “PPACA”), to create a biosimilar market in the US. In fact, the BPCI, itself, has been controversial and just barely survived judicial scrutiny when the US Supreme Court upheld the PPACA on June 28, 2012 in a 5-4 vote. Many commentators speculate whether data exclusivity will overtake patents as the preferred method of intellectual …
The Informational And Institutional Theories Of Off-Label Promotion, Miguel A. Lopez
The Informational And Institutional Theories Of Off-Label Promotion, Miguel A. Lopez
San Diego Law Review
This Article contends that there are two distinct theories of the offense of off-label promotion—the informational theory and the institutional theory. One is concerned with controlling the flow of medical knowledge and the other is concerned with protecting regulatory legitimacy. Different kinds of evidence are key under each theory. I argue that although the Federal Food, Drug, and Cosmetic Act (FD&C Act) and its accompanying regulations emphasize the informational theory, federal prosecutors rely more heavily on the legal arguments that underpin the institutional theory of enforcement. A corollary to this contention is that the informational theory of off-label promotion does …
Honey, It’S All The Buzz: Regulating Neighborhood Beehives, Patricia E. Salkin
Honey, It’S All The Buzz: Regulating Neighborhood Beehives, Patricia E. Salkin
Patricia E. Salkin
Beekeeping’s popularity has surged in recent years, perhaps culminating in the introduction of the first ever White House bee hive. Local Apiaries provide a wide variety of benefits to communities, ranging from pollination services for gardens to producing honey that can be used in a wide array of foods and products. Apiaries are not always welcome in a community, however, perhaps because of their potential to cause a nuisance, or to harm crops or people. Although beekeeping regulation implicates both state and federal concerns a number of localities have developed unique and practical regulations that promote backyard beekeeping, while maximizing …
Verify, Then Trust: How To Legalize Off-Label Drug Marketing, Fazal Khan, Justin Holloway
Verify, Then Trust: How To Legalize Off-Label Drug Marketing, Fazal Khan, Justin Holloway
Fazal Khan
This article proposes a novel framework for more broadly securing the benefits of “off-label” drug usage while mitigating the harms inherent to this practice. Once the FDA approves a drug, doctors can prescribe for it any indication they think is reasonable, even uses that have not been thoroughly tested. The FDA bans the marketing or promotion for off-label uses by drug companies precisely because such uses have not been validated to be safe or effective through the regulatory process. Further, there are serious concerns with validity of industry-sponsored off-label research related to practices such as ghostwriting, gag-clauses on researchers, and …
Commercial Freedom Of Speech Vs. Consumers' Right To Know: Milking The First Amendment For All It's Worth, Jessie Nibley
Commercial Freedom Of Speech Vs. Consumers' Right To Know: Milking The First Amendment For All It's Worth, Jessie Nibley
Jessie Nibley
The FDA's antagonism toward mandatory disclosure by food producers of information consumers want has left states to institute their own laws and policies to ensure consumers can make purchasing decisions based on all of the facts they deem important. However, these state laws face First Amendment challenges by food manufacturers who fear that consumers may shun their products if given too much information about certain foods and how they are produced. The First Amendment interests of consumers and food producers are thus at odds and must be balanced. This paper examines the approaches of two Circuits addressing state labeling regimes …
Room For Two In Tobacco Control: Limits On The Preemptive Scope Of The Proposed Legislation Granting Fda Oversight Of Tobacco, Christopher N. Banthin, Richard A. Daynard
Room For Two In Tobacco Control: Limits On The Preemptive Scope Of The Proposed Legislation Granting Fda Oversight Of Tobacco, Christopher N. Banthin, Richard A. Daynard
Richard A. Daynard
This article examines the public health authority states have to reduce tobacco use in light of the Food and Drug Administration's oversight of tobacco. The authors point out that states have achieved dramatic reductions in tobacco use in the past with little assistance from federal authorities. Indeed, often federal statutes impeded state efforts. The authors examine the preemptive scope of FDA oversight and conclude that states retain and, in some cases, actually improve their legal options for reducing tobacco use under the FDA legislation.
Reassessing Safety For Nanotechnology Combination Products: What Do Biosimilars Add To Regulatory Challenges For The Fda, Jordan Paradise
Reassessing Safety For Nanotechnology Combination Products: What Do Biosimilars Add To Regulatory Challenges For The Fda, Jordan Paradise
Saint Louis University Law Journal
No abstract provided.
The Biologics Price Competition And Innovation Act Of 2009: Legislative Imprudence, Patent Devaluation, And The False Start Of A Multi-Billion Dollar Industry, Brian F. Mcmahon
The Biologics Price Competition And Innovation Act Of 2009: Legislative Imprudence, Patent Devaluation, And The False Start Of A Multi-Billion Dollar Industry, Brian F. Mcmahon
Kentucky Law Journal
No abstract provided.
Fda Accelerated Approval Program: Why Brake When You Can Get A Mandate?, Keren Frumkin
Fda Accelerated Approval Program: Why Brake When You Can Get A Mandate?, Keren Frumkin
Keren F. Bisnauth
The FDA approval process is designed to ensure that the drugs released for public consumption are safe and effective. In 1992, the FDA implemented the Accelerated Approval process in order to expedite the approval of drugs to aid patients with life-threatening illnesses, who have little to gain from lengthy approval processes, and who cannot risk worsening health conditions. However, the questionable post-approval practices of drug manufacturers, coupled with the lax FDA enforcement of its required follow-up protocols have raised doubts as to the true value of expedited approval procedures, as well as an influx of drug recalls and lawsuits. In …
Incentivizing The Utilization Of Pharmacogenomics In Drug Development, Valerie Gutmann Koch
Incentivizing The Utilization Of Pharmacogenomics In Drug Development, Valerie Gutmann Koch
Journal of Health Care Law and Policy
No abstract provided.
A Vaccine Approach To The Reverse Payment Illness, Scott Bergeson
A Vaccine Approach To The Reverse Payment Illness, Scott Bergeson
Richmond Journal of Law & Technology
Big Brand Name develops and files a patent for a drug that kills bacteria in an innovative way. The drug is groundbreaking and potentially marketable, so Big Brand Name incurs the enormous cost (estimated at $868 million) and time of drug discovery research and safety determinations of clinical trials to bring the drug to market. Small Generic Company wants to sell the same drug but must wait until Big Brand Name’s patent expires or, in the alternative, Small Generic Company can file an Abbreviated New Drug Application (“ANDA”) with the FDA and allege Big Brand Name’s patent is invalid or …
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
A Thousand Tiny Pieces: The Federal Circuit’S Fractured Myriad Ruling, Lessons To Be Learned, And The Way Forward, Jonathan R. K. Stroud
IP Theory
No abstract provided.
Superweeds And Suspect Seeds: Does The Genetically-Engineered Crop Deregulation Process Put American Agriculture At Risk, Margaret Sova Mccabe
Superweeds And Suspect Seeds: Does The Genetically-Engineered Crop Deregulation Process Put American Agriculture At Risk, Margaret Sova Mccabe
Law Faculty Scholarship
The federal government’s regulatory approach to genetically engineered (GE) crops, known as “The Framework”, is now twenty-five years old. Despite two and half decades of a consistent regulatory regime, GE crop and food regulation remains controversial. This article suggests that regulatory science and its tenets of independence, transparency, and public science should guide reforms of The Framework so that it is an efficient and reliable regulatory system. The article has four parts: 1) it provides a brief overview of the history of GE crop regulation; 2)it describes the key attributes of The Framework and related regulatory documents, with particular focus …
Drug-Drug Interaction Alerts: Emphasizing The Evidence, Sharona Hoffman, Andy Podgurski
Drug-Drug Interaction Alerts: Emphasizing The Evidence, Sharona Hoffman, Andy Podgurski
Faculty Publications
Many analysts and users of contemporary clinical decision support ("CDS") systems have expressed grave concerns about the technology’s efficacy and functionality. Alerts generated by CDS systems are often inaccurate, and an excess of alerts leads some physicians to experience "alert fatigue" and to turn off CDS altogether. This article formulates recommendations to improve drug-drug interaction (DDI) alerts.
The paper comments upon a proposal by Susan Ridgely and Michael Greenberg, who call for the development of a consensus-based "clinically significant drug-drug interaction list" that could generate limited liability protection for users. We argue that instead of creating a list of always-contraindicated …
Direct-To-Consumer Genetic Testing: Learning From The Past And Looking Toward The Future, Stephanie Bair
Direct-To-Consumer Genetic Testing: Learning From The Past And Looking Toward The Future, Stephanie Bair
Faculty Scholarship
A decade after the complete sequencing of the human genome, we have seen a proliferation of genetic testing services marketed directly to the consumer and purporting to use genetic information to generate individualized health information. These tests have been subject to only minimal regulation, despite the fact that scientists and policymakers have serious concerns about both the clinical effectiveness of the tests and the safety of releasing certain types of health information to the public without the supervision of a health care professional. Proponents of minimal regulation argue that the tests allow for patient autonomy and privacy of genetic information, …
Honey, It’S All The Buzz: Regulating Neighborhood Beehives, Patricia E. Salkin
Honey, It’S All The Buzz: Regulating Neighborhood Beehives, Patricia E. Salkin
Scholarly Works
Beekeeping’s popularity has surged in recent years, perhaps culminating in the introduction of the first ever White House bee hive. Local Apiaries provide a wide variety of benefits to communities, ranging from pollination services for gardens to producing honey that can be used in a wide array of foods and products. Apiaries are not always welcome in a community, however, perhaps because of their potential to cause a nuisance, or to harm crops or people. Although beekeeping regulation implicates both state and federal concerns a number of localities have developed unique and practical regulations that promote backyard beekeeping, while maximizing …
The Drugs Stop Here: A Public Health Framework To Address The Drug Shortage Crisis, Sharona Hoffman
The Drugs Stop Here: A Public Health Framework To Address The Drug Shortage Crisis, Sharona Hoffman
Faculty Publications
Drug shortages are emerging as a major public health threat. Grave concern has been expressed by the medical community and government officials, and the crisis has been highlighted in recent media stories. Nevertheless, little has been written to date in the legal literature about the drug shortage crisis, and this timely article begins to fill this gap. It provides a thorough analysis of the origins and implications of the drug shortage problem and formulates a multi-layered approach to addressing it. The article argues that drug shortages result from a combination of market failures and regulatory constraints. It proposes a blend …
Interests In The Balance: Fda Regulations Under The Biologics Price Competition And Innovation Act, Parker Tresemer
Interests In The Balance: Fda Regulations Under The Biologics Price Competition And Innovation Act, Parker Tresemer
Parker Tresemer
Recent biotechnology advances are yielding potentially life-saving therapies, but without FDA regulations designed to minimize product costs, patients will continue to be unable to afford these expensive biologic products. Many believe that these prohibitive costs stem from weak competition from generic biologic products, also known as follow-on biologics. To correct this deficiency, and to address the often conflicting regulatory and policy concerns associated with biologic products, Congress enacted the Biologics Price Competition and Innovation Act. The Act created an abbreviated approval pathway for biologic products and, if effective, could increase competition while driving down product costs. But legislation alone is …
The Vaccine Efficacy Standard: Ethical And Policy Concerns In Light Of Emerging Vaccines, Vincent Y. Ling
The Vaccine Efficacy Standard: Ethical And Policy Concerns In Light Of Emerging Vaccines, Vincent Y. Ling
Vincent Y. Ling
An efficacy showing is one prerequisite for market approval of vaccines in the United States. The Food and Drug Administration’s current standard for efficacy, however, is low and vague, which allows partially effective vaccines on the market. The use of partially effective vaccines poses an ethical dilemma, especially when more effective vaccines are, or will be, available. Non-regulatory forces contribute to a higher efficacy showing in practice, but more instructive efficacy regulation will be necessary as partially effective vaccines become a viable health care option. A growing emphasis on comparative effectiveness research under the Patient-Centered Outcomes Research Institute (“PCORI”), established …
Fda Accelerated Approval Program: Why Brake When You Can Get A Mandate?, Keren Frumkin
Fda Accelerated Approval Program: Why Brake When You Can Get A Mandate?, Keren Frumkin
Keren F. Bisnauth
The FDA approval process is designed to ensure that the drugs released for public consumption are safe and effective. In 1992, the FDA implemented the Accelerated Approval process in order to expedite the approval of drugs to aid patients with life-threatening illnesses, who have little to gain from lengthy approval processes, and who cannot risk worsening health conditions. However, the questionable post-approval practices of drug manufacturers, coupled with the lax FDA enforcement of its required follow-up protocols have raised doubts as to the true value of expedited approval procedures, as well as an influx of drug recalls and lawsuits. In …